In a regulatory filing made after market hours yesterday, the company informed that it has been granted patent for an invention entitled “A freeze dried parenteral composition of Omadacycline Tosylate and process for preparation thereof” on September 14, 2023 for the term of 20 years effective from 19 April 2021 in accordance with the provisions of the Patents Act, 1970.

Omadacycline is a new aminomethylcycline as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections.

Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.

The company's net profit had declined 2.04% to Rs 20.62 crore while net sales rose 17.99% to Rs 195.02 crore in Q1 June 2023 over Q1 June 2022.